Drug Trial Radar · NCT06530797
A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jul 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,000
Planned (sponsor's estimate)
Start
Aug 1, 2024
Primary completion
Sep 1, 2026
Study completion Sep 1, 2026
Sponsor
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 31, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
The purpose of this observational study is to evaluate the safety and efficacy of Adebrelimab Injection in extensive-stage small cell lung cancer (ES-SCLC) under real-world conditions. Specifically, the study aims to assess the treatment of Adebrelimab Injection across various subgroups of ES-SCLC patients. The goal is to provide information on treatment patterns and effectiveness in real-life settings, explore potential predictive or prognostic biomarkers, and preliminarily evaluate the pharmacoeconomic indicators of Adebrelimab Injection treatment for extensive-stage small cell lung cancer.
Conditions
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Interventions
First-line Adebrelimab regiment for advanced stage ES-SCLCDrug
First-line Adebrelimab in any regiment for advanced stage ES-SCLC
Second-line and beyond Adebrelimab regiment for advanced stage ES-SCLCDrug
Second-line and beyond Adebrelimab in any regiment for advanced stage ES-SCLC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety (The occurrence of ≥3 grade AEs)Time frame: From August 2024, patients will be followed up for 90 days after the last use of Adebrelimab
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.